PipelineRSSMay 7
ALS treatment tazbentetol gets FDA fast track status
The FDA has given fast-track status to tazbentetol, a new oral medication being developed by Spinogenix for ALS (a disease that affects nerve cells that control muscles). Fast-track status means the FDA will review this drug more quickly and the company can talk with FDA regulators more often during development. This designation is given to treatments for serious diseases where there aren't many good options available.
WHY IT MATTERSFast-track designation could bring tazbentetol to ALS patients 1-2 years sooner than standard FDA review timelines, which is critical since ALS progresses rapidly and patients have limited treatment options.